Advancing Next-Generation Cell Therapy
1.CAR001 ( Allogeneic CAR.BiTE γδ T-cell therapy): Ready to use, no lymphocyte removal or HLA matching required.
Clinical progress：
(1). Phase 1 Completed：
●15 patients with relapsed/refractory solid tumors, all having failed at least 2 lines of standard-of-care therapies.
●Indications included CRC, GBM, TNBC, and NSCLC.
●Demonstrated a favorable safety profile.
(2). Achieve one Complete Response (CR)：
●One patient with recurrent glioblastoma (GBM) achieved complete remission (CR), with clinical benefit lasting for more than 300 days since the first dose.
(3). Transition to Phase IIa：
●The Safety Monitoring Committee (SMC) has approved entry into Phase lla dose expansion.
Detailed literature：https://pubmed.ncbi.nlm.nih.gov/37078788/
2.EXO-001 ( Enabling CAR-T cells to be generated in the body )：
After exosomes are administered in vitro and enter the in vivo circulation, they deliver the nano-antibody CAR.BiTE gene to T cells, completing immune programming in vivo, training T cells to transform into multi-target CAR-T cells, and then entering solid tumors to kill cancer cells and disrupt the tumor microenvironment.
Global footprint of in vivo CAR-T technology：
Detailed literature：https://pubmed.ncbi.nlm.nih.gov/41632088/